Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Oasmia Pharmaceutical AB (publ)
  6. News
  7. Summary
    OASM   SE0000722365


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Oasmia Pharmaceutical : strengthens internal capabilities with the appointments of Head of Clinical Development & Head of Regulatory Affairs

08/26/2021 | 01:00am EDT

- Key roles reinforce Oasmia’s capacity to progress and expand its clinical-stage oncology portfolio

Solna, Sweden, August 26, 2021 – Oasmia Pharmaceutical AB, an oncology-focused specialty pharmaceutical company, today announces the appointments of Kia Bengtsson as Head of Clinical Development and Johanna Röstin as Head of Regulatory Affairs with effect from October 1, 2021. The appointments significantly strengthen Oasmia’s internal drug development expertise as the company progresses its portfolio of cancer therapies through the clinic and evaluates opportunities to further expand the pipeline through M&A and in-licensing.

Kia Bengtsson commented: “Oasmia is building a strong oncology-focused business, with important international clinical studies underway and clear ambitions to build a broad cancer portfolio. I look forward to joining the company at this exciting time and to supporting its growth strategy.”

Kia Bengtsson was previously Director, Drug Development, at the Swedish nanotechnology company Nanologica, with responsibility for pre-clinical and clinical development. In more than 20 years at leading pharma and biotech companies, Kia has worked on the development of innovative therapies including Somatuline™ for the treatment of neuroendocrine tumors and Decapeptyl™ for the treatment of prostate cancer. She held leading positions in drug development and clinical operations at Ipsen, AstraZeneca and Eurocine Vaccines. Kia began her career as a registered nurse at Karolinska University Hospital.

Johanna Röstin said: “Oasmia is putting in place a first-class in-house team to help it bring new options to patients with ovarian and prostate cancer and to expand its portfolio of innovative products. This is a great opportunity to help build a leading oncology company focused on innovation.”

Johanna Röstin joins Oasmia from OxThera AB, where she is Director of CMC, Program Management and Regulatory. Johanna spent 10 years at Swedish Orphan Biovitrum AB (Sobi), where she was regulatory responsible for one of Sobi’s leading biological products commercialized in the EU and US as Global Senior Regulatory Affairs Manager. She was Regulatory CMC expert for commercial- and development-stage biological products. She has also worked for Pharmacia and Biovitrum. Johanna has an M.Sc in chemical engineering / biotechnology and a Licentiate degree in biotechnology from the KTH Royal Institute of Technology in Stockholm.

Dr Heidi Ramstad, Chief Medical Officer at Oasmia, commented: ’’We are delighted to welcome Kia and Johanna to Oasmia as we enter a new phase of clinical development with our oncology portfolio. We’ll also benefit from their extensive industry experience as we continue to broaden our pipeline and establish Oasmia as a leading, sustainable oncology company focused on bringing new treatment approaches to patients’’.

For More Information: 

Oasmia Pharmaceutical AB 
Francois Martelet, Chief Executive Officer 
Phone: +46 18-50 54 40 
E-mail: IR@oasmia.com

Consilium Strategic Communications 
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700 
E-mail: oasmia@consilium-comms.com

About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has an emerging pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.oasmia.com.

© Modular Finance, source Nordic Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
OASMIA PHARMACEUTICAL AB (PUBL) -4.68% 2.26 Delayed Quote.-42.45%
SWEDISH ORPHAN BIOVITRUM AB (PUBL) 0.30% 235 Delayed Quote.41.06%
10/21OASMIA PHARMACEUTICAL : announces global settlement of all disputes with MGC Capital, form..
10/20OASMIA PHARMACEUTICAL : Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutic..
10/08OASMIA PHARMACEUTICAL (OASM) : Focused on pillars of growth
10/01OASMIA PHARMACEUTICAL : Naventus LifeScience Summit
09/24OASMIA PHARMACEUTICAL : to present at Naventus Life Science Summit on September 29
09/20OASMIA PHARMACEUTICAL : Notice of Extraordinary General Meeting in Oasmia Pharmaceutical A..
09/17OASMIA PHARMACEUTICAL : signs agreement with FarmaMondo to commercialize Paclical® in Russ..
09/17Oasmia Pharmaceutical AB Signs Agreement with FarmaMondo to Commercialize Paclical® in ..
09/07OASMIA PHARMACEUTICAL : Presentation på Aktiedagen Stockholm
08/31OASMIA PHARMACEUTICAL : to present at Aktiedagen Stockholm on September 7
More news
Sales 2021 10,2 M 1,19 M 1,19 M
Net income 2021 -173 M -20,1 M -20,1 M
Net cash 2021 130 M 15,2 M 15,2 M
P/E ratio 2021 -5,65x
Yield 2021 -
Capitalization 1 013 M 118 M 118 M
EV / Sales 2021 86,6x
EV / Sales 2022 25,1x
Nbr of Employees 25
Free-Float 61,3%
Duration : Period :
Oasmia Pharmaceutical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OASMIA PHARMACEUTICAL AB (PUBL)
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 0
Last Close Price 2,26 SEK
Average target price 5,70 SEK
Spread / Average Target 152%
EPS Revisions
Managers and Directors
François R. Martelet Chief Executive Officer
Fredrik Järrsten Chief Financial Officer
Karl Anders Olof Härfstrand Chairman
Mikael Asp Chief Technology Officer
Carina Eklöw Director-Global Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON3.83%430 148
ROCHE HOLDING AG15.79%339 425
PFIZER, INC.16.27%240 303
NOVO NORDISK A/S56.55%239 079